Список проголосовавших за комментарий " Durect resumed with a Buy at H.C. Wainwright; tgt $3 (1.02)H.C. Wainwright resumes coverage of DRRX with a Buy and sets target price at $3. Firm's analysis suggests that the Street is barely accruing sufficient value for the Phase 3 Posimir program, while essentially ignoring the novel epigenetic program, thereby creating a free call option for this highly-differentiated proprietary discovery platform. They employ a rNPV valuation model to estimate the intrinsic value of DRRX shares, and arrive at their $3 PT, based on: 1) $1.71 per share, driven by U.S. sales of DUR-928 for AKI (2021 launch; 25% probability of success (POS), $1.1B peak sales); 2) $0.70 per share, driven by royalties on U.S. sales of Posimir (assumes future partner; 75% POS, $500M peak sales; ~22% peak royalties); and 3) $0.52 representing essentially the annuity value of marketed legacy products."